Healthcare providers, administrators, and investors are urged to meticulously examine their financial arrangements to determine if their compensation structures adequately satisfy the safe harbor provisions of the Anti-Kickback Statute (AKS). This critical reminder, emphasized by an April update from federal healthcare officials, signals a heightened focus on the nuances of compliance and a potential shift in enforcement priorities, according to attorneys June S. Santiago and Kaleb Rasmussen of Spencer Fane.
The complex landscape of healthcare fraud and abuse statutes, including the AKS, is a constant challenge for physician groups, hospital administrators, and healthcare investors. The AKS, a criminal statute, prohibits knowingly and willfully offering, paying, soliciting, or receiving any form of remuneration—be it cash, gifts, rent, or fees—with the intent to induce patient referrals for services reimbursed by federal healthcare programs such as Medicare or Medicaid. Violations can lead to severe consequences, including imprisonment and substantial financial penalties for both payers and recipients of such remuneration.
While the AKS has broad applicability, a key element for prosecution is the specific intent to violate the statute. The statute itself outlines numerous provisions designed as "safe harbors," offering protection from prosecution for arrangements that meet stringent requirements. Compliance with these safe harbors is entirely voluntary; failure to meet a safe harbor does not automatically render an arrangement illegal. However, the absolute nature of safe harbor requirements—where all conditions must be met for protection—means that many arrangements unfortunately fall outside their protective umbrella.
Historically, many healthcare entities have relied on the principle that compensating services at Fair Market Value (FMV) would shield them from AKS prosecution. The prevailing logic suggested that if remuneration was equivalent to the market rate for goods or services, it could not simultaneously serve as an inducement for referrals, as there would be no "overage" to attribute to such inducements. This interpretation, however, has been directly challenged by recent guidance.
In April, the U.S. Department of Health and Human Services Office of Inspector General (OIG) published an update to its Frequently Asked Questions (FAQs) that reiterated and further clarified existing guidance. The update unequivocally states that an arrangement can violate the AKS even if all payments are consistent with FMV. The OIG periodically revises its FAQs to provide subregulatory guidance reflecting current market trends and evolving enforcement priorities.
The OIG’s updated FAQ explicitly addresses this common misconception: "Some health care industry stakeholders have taken the position that, so long as the remuneration offered, paid, solicited, or received in an arrangement is consistent with fair market value, there is no unlawful remuneration under the Federal anti-kickback statute, and consequently, there can be no liability under the Federal anti-kickback statute. OIG’s guidance has been consistent and unwavering that fair market value is not a dispositive defense under the Federal anti-kickback statute."
This recent clarification underscores that AKS compliance extends beyond merely ensuring that compensation is at FMV. It is noteworthy that the AKS statute itself does not explicitly use the term "fair market value." Instead, FMV is considered a foundational prerequisite that each component of remuneration must satisfy to align with applicable safe harbor requirements. The OIG’s reiteration emphasizes that while all payments related to referrals funded by federal healthcare programs should indeed be at FMV, the OIG considers a multitude of additional factors when assessing potential violations. This suggests a necessary recalibration of industry reliance on FMV as the sole determinant of compliance.
Anticipated Impact on Healthcare Arrangements
The OIG’s renewed emphasis signals a significant shift in how arrangements falling outside explicit safe harbor protections will be evaluated. The commercial reasonableness and bona fide business purpose tests are expected to play a far more prominent role in the OIG’s fact-based analysis.
Commercial Reasonableness: This test probes the underlying rationale for a payment. It asks whether the arrangement makes business sense independent of any potential for generating patient referrals. An arrangement is deemed commercially reasonable if well-informed parties, even if not in a position to refer business to each other, would find it sensible to enter into it. This moves beyond a simple price comparison to an assessment of the overall business justification.
Bona Fide Business Purpose: This criterion scrutinizes whether the services rendered are necessary, genuine, and actually performed. It requires a demonstration that the arrangement serves a legitimate business need and that the services contracted for are not merely a pretext for a referral-inducing payment.
These tests demand a more in-depth examination than a simple FMV analysis, which primarily focuses on the amount of compensation and its alignment with market rates. An arrangement that is compensated at FMV but lacks commercial reasonableness or fails to fulfill a bona fide business purpose is now more likely to be deemed a violation of the AKS.
Illustrative examples of arrangements that could face scrutiny include:
- Leasing office space significantly larger than what is commercially reasonable for the intended use, even if the rental rate per square foot is at FMV.
- Compensating multiple medical directors at FMV for services when only one position is demonstrably needed to meet the organization’s operational requirements.
- Paying a referring physician FMV compensation for 50 hours of consulting services per month when the actual business need only warrants five hours of work.
In these scenarios, the FMV compensation would not shield the arrangement from scrutiny if it fails to meet the standards of commercial reasonableness or a bona fide business purpose.
The "One Purpose Rule" and Intensified Scrutiny
Beyond the increased application of commercial reasonableness and bona fide business purpose tests, the OIG is expected to place greater emphasis on the "one purpose rule." This rule dictates that if even one purpose of a payment is to induce referrals, the entire arrangement is considered illegal.
This principle has profound implications. Even if an arrangement is compensated at FMV, is commercially reasonable, and serves a bona fide business purpose, the presence of a single underlying intent to induce referrals can render the entire arrangement unlawful. The OIG need only demonstrate that a portion of the motivation for the arrangement was to secure referrals. Evidence such as an internal email suggesting the arrangement could improve referrals, regardless of multiple legitimate business objectives, could be sufficient to trigger AKS liability, overriding FMV and commercial reasonableness considerations.
Increased Scrutiny of Percentage-Based Fees
Furthermore, the OIG anticipates increased scrutiny of compensation models that utilize percentage-based fees, particularly those that fluctuate based on the volume or value of referrals. As the OIG’s focus intensifies on the intent behind financial arrangements, these percentage-based fee structures may be more frequently interpreted as circumstantial evidence of an intent to influence referrals. This, in turn, could lead to a greater perceived share in referral profits, making such arrangements more vulnerable to AKS prosecution.
The evolving enforcement landscape, as highlighted by the OIG’s April FAQ update, necessitates a comprehensive and proactive approach to AKS compliance. Healthcare entities must move beyond a singular focus on Fair Market Value and instead conduct a thorough evaluation of their compensation structures through the lenses of commercial reasonableness, bona fide business purpose, and the overarching intent of their arrangements. Failure to adapt to these clarified expectations could expose organizations and individuals to significant legal and financial risks.
This article was adapted with permission from Spencer Fane.
